Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N. Grisham, Brian M. Slomovitz, Nicole Andrews, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 9, pp. 1331-1344
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer
Diletta Fumagalli, Aarthi S Jayraj, Elena Olearo, et al.
International Journal of Gynecological Cancer (2025), pp. 101664-101664
Closed Access | Times Cited: 1
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Robert L. Hollis, Richard Elliott, John C. Dawson, et al.
Gynecologic Oncology (2024) Vol. 186, pp. 42-52
Open Access | Times Cited: 5
Recent clinical and molecular findings in low-grade serous ovarian carcinoma including prospects for personalized medicine using cancer organoids
Kentaro Nakayama, Tomoka Ishibashi, Masako Ishikawa, et al.
Academia oncology. (2025) Vol. 2, Iss. 1
Closed Access
Controversies in the Management of Serous Borderline Tumors and Low-Grade Serous Ovarian Cancer
Narthana Ilenkovan, Neil Ryan, Patricia Roxburgh, et al.
International Journal of Gynecological Cancer (2025) Vol. 35, Iss. 3, pp. 101673-101673
Open Access
Serous Neoplasms of the Ovary
Preetha Ramalingam
(2025), pp. 1-38
Closed Access
Optimized derivative fast Fourier transform: Splitting singlet-appearing resonances to genuine multiplets in ovarian NMR spectra from encoded time signals
Dževad Belkić, Karen Belkić
Journal of Mathematical Chemistry (2025)
Open Access
Cytologic Histotyping of Gynecologic Malignancies in Peritoneal Fluids Is Reliable When Compared to Its Corresponding Surgical Specimen
Thomas F. Sabljic, Si Kei Lou
Diagnostic Cytopathology (2025)
Open Access
Fertility Sparing Medical Management Options in Gynecologic Cancers
Ana Kouri, Janelle Darby
Current Treatment Options in Oncology (2025)
Open Access
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma.
Elizabeth Tubridy, Stefan Gysler, Nawar Latif, et al.
International Journal of Gynecological Cancer (2025), pp. 101798-101798
Closed Access
Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma
Alexander J. Neil, Dingani Nkosi, Ju‐Yoon Yoon, et al.
Histopathology (2025)
Closed Access
The INDEPSO-ISPSM Consensus on Peritoneal Malignancies—Management of Advanced Epithelial Ovarian Cancer
Neha Kumar, Aditi Bhatt, Snita Sinukumar, et al.
Indian Journal of Surgical Oncology (2025)
Closed Access
Beyond the SNR-resolution uncertainty principle: Optimized derivative fast Fourier transform for NMR diagnostics in medicine
Dževad Belkić, Karen Belkić
Journal of Mathematical Chemistry (2025)
Open Access
Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment
Vivek Podder, Rachel N. Grisham, Robert L. Coleman, et al.
International Journal of Gynecological Cancer (2025), pp. 101938-101938
Closed Access
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?
Tine Ottenbourgs, Els Van Nieuwenhuysen
Cancers (2024) Vol. 16, Iss. 10, pp. 1862-1862
Open Access | Times Cited: 3
A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
Manrose Singh, Samantha Cornwell, Ariel Shaddaie, et al.
Gynecologic Oncology Reports (2024) Vol. 54, pp. 101417-101417
Open Access | Times Cited: 3
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel N. Grisham, Bradley J. Monk, Els Van Nieuwenhuysen, et al.
International Journal of Gynecological Cancer (2024), pp. ijgc-005919
Open Access | Times Cited: 3
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
Sarah Andres, Lindsey Finch, Alexia Iasonos, et al.
Gynecologic Oncology (2024) Vol. 189, pp. 30-36
Closed Access | Times Cited: 2
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial
Brad J. Nakamura, Rosemary Senguttuvan, Nora Ruel, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
Kathleen I. Pishas, Karla J. Cowley, Marta Llaurado-Fernandez, et al.
Scientific Data (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
Arina Onoprienko, Thomas Bartl, Christoph Grimm, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3268-3268
Open Access | Times Cited: 2
Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers
Mohamed A. A. A. Hegazi, Fabio Pasqualini, Gianluigi Taverna, et al.
Discovery Medicine (2024) Vol. 36, Iss. 182, pp. 632-632
Open Access | Times Cited: 1
Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
Shashank Sama, Sterling Rosqvist, Talicia Savage, et al.
Gynecologic Oncology Reports (2024) Vol. 53, pp. 101412-101412
Open Access | Times Cited: 1
Targeted Therapies in Low-Grade Serous Ovarian Cancers
Anna Gonzalez, Christa Nagel, Paulina Haight
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 7, pp. 854-868
Open Access | Times Cited: 1
Steady spectra of supreme resolution and lowest noise in high-order optimized derivative fast Fourier transform for ovarian NMR spectroscopy
Dževad Belkić, Karen Belkić
Journal of Mathematical Chemistry (2024) Vol. 62, Iss. 8, pp. 2056-2080
Open Access | Times Cited: 1
The development and progression of low-grade serous ovarian carcinoma
Kwong‐Kwok Wong, David M. Gershenson
Academia oncology. (2024) Vol. 1, Iss. 1
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top